18 September 2024
18 September 2024
BMS paid $150m upfront to enter a collaborative development deal for IMA401 with Immatics in 2021.
Bicara was one of three biotechs that went public last week in one of the busiest biotech IPO windows this year.
The US-based pharmacy benefit manager (PBM) claims that the FTC鈥檚 July 2024 report is riddled with 鈥渇alse and misleading claims鈥� about the PBM industry.
The clinical hold was placed on three studies investigating azenosertib in June after two patients died due to presumed sepsis.
The latest application is supported by interim data from the DREAMM-7 and DREAMM-8 Phase III trials.
The partnership will see the application of AI-enabled screening to address bioavailability issues with Equillium鈥檚 cytokine-targeting peptide.
The partnership will leverage Vivtex' gastrointestinal robotic interface system.
Further filings in the region for first-line oesophageal squamous cell carcinoma and gastric cancer are anticipated.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
